ARTICLE | Clinical News

Jazz gets PDUFA date for excessive sleepiness candidate

March 9, 2018 6:37 PM UTC

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) said FDA accepted for review an NDA for solriamfetol (JZP-110) to treat excessive sleepiness associated with narcolepsy or obstructive sleep apnea. The PDUFA date is Dec. 20.

Solriamfetol is a phenylalanine derivative that acts as a selective dopamine and norepinephrine reuptake inhibitor (DNRI)...